Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-2.45 · Revenue $1.90M · 2 analysts
Est. EPS $-2.70 · Revenue $2.40M · 2 analysts
Est. EPS $-9.52 · Revenue $4.30M · 2 analysts
Est. EPS $-2.37 · Revenue $1.20M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.3M | +550.0% | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-140.1M | -108.3% | -9.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | -91.0% | +91.3% | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -10386.5% | +93.7% | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -10773.5% | -101.3% | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-129.8M | +34.1% | +21.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -9986.5% | +89.9% | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 1338.8% | +22122.3% | +64.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 3.93x | -0.2% | -21.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $146.5M | -19.0% | -16.2% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -9.04 vs -9.01 | -0.3% | -2.34 vs -2.28 | -2.6% |
| Revenue Surprise | $1.3M vs $1.3M | 0.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Vuori Kristiina MD | director | Stock Option (right to buy) | A | 15,000 | $95.22 |
| Jun 3, 2026 | Kayyem Jon Faiz | director | Stock Option (right to buy) | A | 15,000 | $95.22 |
| Jun 3, 2026 | FORSYTH DOUGLAS | director | Stock Option (right to buy) | A | 15,000 | $95.22 |
| Jun 3, 2026 | MANHARD KIMBERLY | director | Stock Option (right to buy) | A | 15,000 | $95.22 |
| Apr 24, 2026 | Matly David | officer: President | Stock Option (right to buy) | A | 50,000 | $129.06 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Mark Paul Lappe | Founder, Chief Executive Officer & Chairman | USD 2,892,473 | Male | 1967 | Active |
David Matly | President | USD 911,655 | Male | 1986 | Active |
Kelly Devine Deck | Executive Vice President, Chief Financial Officer & Treasurer | USD 766,410 | Female | 1980 | Active |
Josep Garcia | Executive Vice President & Chief Clinical Development Officer | — | — | — | Active |
Carlos Bais | EVice President & Chief Scientific Officer | — | — | — | Active |
Ashraf Amanullah | Executive Vice President & Chief Technical Operations Officer | — | — | 1968 | Active |
Bonne Adams | Vice President of Operations | — | Female | 1977 | Active |
Leah Pollema | Vice President, General Counsel & Corporate Secretary | — | Female | — | Active |
Kate Burke | Vice President of Accounting | — | Female | — | Active |
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027 PDUFA date, supported by strong PFS and disease control data. INBRX-106 shows promising early efficacy as a PD-1 enhancer in HNSCC, with pivotal PFS data expected in Q4 2026 and Phase 3 initiation in Q3 2026.
SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with Oxford Finance LLC ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to $500.0 million (the "Credit Facility"). The Second Amendment provides for an additional tranche, in an aggregate principal amount of up to $325.0 million in gross proceeds, (i) $100.0 million of which was funded upon execution of the Second Amendment (the "Term C Loan") and (ii) up to an additional $225.0 million of which may be funded in increments of $50.0 million or more upon the Company's request and at the Lenders' sole discretion (the "Term D Loan").
Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma SAN DIEGO, June 15, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.
